Ben Lamm is the CEO of Colossal Biosciences, a company focused on de-extinction and genetic engineering. As a serial technology entrepreneur, Lamm has founded and led several successful ventures, including Hypergiant, Conversable, and Chaotic Moon. His work spans across various industries, from biotechnology to artificial intelligence, making him a prominent figure in the tech world.
Who is the CEO of Colossal Biosciences?
Ben Lamm is a dynamic entrepreneur with a rich history of founding and leading innovative companies. As the CEO of Colossal Biosciences, he is at the forefront of genetic engineering and de-extinction efforts. Lamm's career began while he was still a senior at Baylor University, and he has since built and sold several companies, including Simply Interactive, Chaotic Moon Studios, Team Chaos, Conversable, and Hypergiant Industries. His ventures span various industries, from creative technology to enterprise AI, showcasing his versatility and forward-thinking approach.
At Colossal, Lamm leverages cutting-edge technologies to tackle significant global challenges, aiming to make a substantial impact on biodiversity and conservation.
Work History
Ben Lamm's extensive work history showcases his diverse experience and leadership across various industries. Here are some of the notable positions he has held:
- Colossal Biosciences - Founder and CEO (2021 - Present)
- Form Bio - Co-founder and Board Member (2022 - Present)
- The Explorers Club - Member Board of Trustees & Fellow (2023 - Present)
- The Explorers Club - Fellow (2021 - 2023)
- Breaking - Co-founder and Board Member (2024 - Present)
- The Planetary Society - Advisory Board Member (2018 - Present)
- Nautilus Magazine - Partner, Owner, & Scientific Advisor (2019 - Present)
- Worlds - Co-Founder (2018 - Present)
- Worlds - Co-Founder & Board Member (2018 - 2023)
- Arch Mission Foundation - Advisory Board Member (2019 - Present)
- Capital Factory - Partner & Board Member (2013 - Present)
- TechStars - Mentor & Investor (2013 - Present)
- Hypergiant - Founder & Board Member (2021 - 2023)
- Hypergiant - Founder, CEO, & Board Member (2018 - 2021)
- Adweek - Advisory Board Member (2018 - 2021)
- The Dallas Entrepreneur Center - Executive Advisor & Mentor (2016 - 2020)
- Conversable - Founder & CEO (2016 - 2018)
- Waterloo Greenway - Board Member (2014 - 2017)
- Booz Allen Hamilton - Special Advisor & Entrepreneur in Residence (2016 - 2017)
- Feel Rich, Inc - Executive Producer, Feel Rich Documentary (2015 - 2017)
- Univ. of Texas Game and Mobile Media Applications Program - Executive Board Member (2014 - 2016)
- Team Chaos - Co-Founder & Partner (2013 - 2016)
- Chaotic Moon Studios - Founder & CEO (2010 - 2016)
- Accenture - Managing Director (2015)
- Sprint Accelerator powered by Techstars - Mentor (2015)
- Fjord - Global Digital Products Lead & Global Management Team (2015)
- Disney Accelerator powered by Techstars - Mentor (2014 - 2015)
- Symbiot Security - Board Member (2009 - 2012)
- Simply Interactive - CEO / Founder (2004 - 2010)
Education History
Ben Lamm's educational journey began at Baylor University, where he pursued a Bachelor of Business Administration (BBA) in Finance and Accounting from 2000 to 2004. During his time at Baylor, Lamm developed a strong foundation in financial principles and accounting practices, which would later support his entrepreneurial ventures. Additionally, he expanded his academic horizons by studying foreign languages, literatures, and business at Universitat d'Alacant from 2000 to 2001. This international experience enriched his understanding of global business dynamics and cultural diversity, further shaping his multifaceted career.
When did Ben Lamm join Colossal Biosciences?
Ben Lamm founded Colossal Biosciences in July 2021, taking on the role of CEO from the company's inception. As of 2023, he has been leading the company for over two years. His tenure at Colossal Biosciences has been marked by significant advancements in genetic engineering and de-extinction efforts, positioning the company at the forefront of biotechnology innovation.